Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02
September 12, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
June 13, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., June 13, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin disease, and...
Autoimmune Disease Patent Granted to Galectin Therapeutics
June 06, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., June 06, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has...
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
April 25, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 25, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin...
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congress™ 2017
April 18, 2017 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., April 18, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, and Exalenz Bioscience (TASE:EXEN),...
Galectin Therapeutics to Present at 29th Annual ROTH Conference
March 09, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., March 09, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis
March 06, 2017 08:30 ET
|
Galectin Therapeutics
Research done in partnership with San Antonio Military Medical Center showed an average 50% PASI reduction by end of 24-week treatment period NORCROSS, Ga., March 06, 2017 (GLOBE NEWSWIRE) --...
Galectin Therapeutics to Present at BIO CEO & Investor Conference
February 08, 2017 08:30 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 08, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Harold...
Galectin Therapeutics Announces Achievement of Key Milestones Related to NASH-CX Clinical Trial
February 01, 2017 08:10 ET
|
Galectin Therapeutics
NORCROSS, Ga., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has generated...
Galectin Therapeutics to Webcast Corporate Update At Annual Meeting of Stockholders
December 08, 2016 08:00 ET
|
Galectin Therapeutics
NORCROSS, Ga., Dec. 08, 2016 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company...